Asset Details
Do you wish to reserve the book?
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
Do you wish to request the book?
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
2018
Overview
The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab.
A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model.
Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = <5 vs NLR = ≥5 was 29.1 (16.2-40.9) vs 24.2(16.1-36.2) months respectively, p<0.001). In addition NLR increased in non-responders after two cycles of nivolumab by 6.6±21.8 as compared to responders (p = 0.027).
Post-treatment ANC, ALC and NLR are independent prognostic factors in NSCLC patients treated with nivolumab. Changes in NLR can be an early biomarker for response in NSCLC patients treated with nivolumab.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antineoplastic Agents, Immunological - therapeutic use
/ Cancer
/ Carcinoma, Non-Small-Cell Lung - blood
/ Carcinoma, Non-Small-Cell Lung - diagnosis
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Female
/ Humans
/ Lung Neoplasms - drug therapy
/ Male
/ Medicine and Health Sciences
/ Non-small cell lung carcinoma
/ Oncology
/ Patients
